Effects of dual sofosbuvir/daclatasvir therapy on, chronic hepatitis C infected, survivors of childhood malignancy

Table 1 Baseline demographics and clinical characteristics, n (%)

Characteristic	Patients total (n = 20)
Age (y): Median (range)	11.5 (8-16)
Sex, male:	10 (50)
Duration (yr) after end of cancer treatment	4 (1- 9)
Type of cancer history
ALL	17 (85)
Hodgkin Lymphoma	2 (10)
Non-Hodgkin Lymphoma	1 (5)
Weight (kg): Median (range)	37 (24-64.5)
Height (cm): Median (range)	137.5 (114-77)
BMI (kg/m2): Median (range)	17.7 (14.56-24.89)
HCV RNA (log10 IU/mL): Mean (SD)	6.09 (0.72)
HCV RNA ≥ 800000 IU/mL	10 (50)
Interferon or ribavirin treatment experience
Naïve:	19 (95)
Non-respondent to IFN Rx	1 (5)
METAVIR Score by Fibroscan
F1	17 (85)
F2	3 (15)
WBCs (× 10⁹/L): Median (range)	7.5 (4.1-13.8)
Hemoglobin (g/dL): Median (range)	12.05 (10-13.8)
Platelet Count (× 10⁹/L): Median (range)	236.5 (66-444)
AST (IU/L): Mean (SD)	50.7 (29.4)
ALT (IU/L): Mean (SD)	54.3 (40.2)
S. Total Bilirubin (mg/dL): Median (range)	0.7 (0.2-1.7)
S. Creatinine (mg/dL): Median (range)	0.65 (0.2-0.8)

ALL: Acute lymphoblastic leukemia; BMI: Body mass index; WBCs: White blood cells; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; S: Serum; SD: Standard deviation; mg: Milligrams; DL: Deciliter; L: Liter; IU: International units.